Human insulin is synthetic insulin manufactured in laboratories by growing the insulin protein with the help of E. coli bacteria. The global human insulin market is driven by the increasing prevalence and occurrence of Diabetes Mellitus (DM) and the increasing demand for human insulin. Additionally, the increasing technological innovations and the rising awareness and screening for diabetes mellitus also drive the market. Growing emphasis on diabetes management including new treatment options and rising geriatric population are various other factors that accelerate the growth of the market.
The global Human Insulin Market is expecting a healthy growth at a CAGR of 12.1% during forecast period.
Segmentation
The global human insulin market is segmented by type, indication, and end-users.
On the basis of type, it is segmented into accessories and devices.
On the basis of methods, it is segmented into traditional human insulin and modern human insulin.
On the basis of applications, it is segmented into type 1 diabetes and type 2 diabetes.
On the basis of end-users, it is segmented hospitals, forensic laboratories, research centers, and others.
Key players
Some of the major players in the global human insulin market are Biocon Ltd, Tonghua Dongbao Pharmaceuticals Co., Ltd., ADOCIA, Merck & Co, Julphar, Pfizer, Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Oramed Pharmaceuticals, Inc, Novo Nordisk A/S, and Sanofi.
Request Customization
Get a Sample
Get a Sample
Request Customization